Results for “ ”

Entry Author Date Location
Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More 03/27/20 National
With $80M, ReCode Looks to Advance RNA Therapies for Lung Diseases 03/26/20 San Francisco
Oncology Needs Combo Therapies & More Data Analysis, Says Bio-Europe Spring Panel 03/26/20 Boston
CytomX Lands $80M to Kick Off Cancer Drug R&D Pact With Astellas 03/24/20 San Francisco
Palforzia Peanut Allergy Immunotherapy: Aimmune CEO on REMS, Manufacturing 03/24/20 National
Bio Roundup: Coronavirus Diagnostics, Therapeutics, Vaccines & More 03/20/20 National
Eureka Partners With Lyell to Tackle Tricky Solid Tumor Cell Therapies 03/20/20 San Francisco
As the Commercial Real Estate Market Slumps, Look for a More Tenant-Friendly Future 03/19/20 Boston
Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More 03/13/20 National
Kymera Closes $102M Round to Bring Protein-Busting Drugs to the Clinic 03/12/20 Boston
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More 03/06/20 National
Culture Biosciences Adds $15M for New Software, Bioreactor Expansion 03/05/20 San Francisco
Amunix Raises $73M to Bring Safer T Cell Engagers to Solid Tumors 03/04/20 San Francisco
Novartis Leads $100M Round for Fibrosis-Focused Pliant Therapeutics 03/03/20 San Francisco
National Xconomy Awards Now Accepting Nominations for the Best in Biotech 03/03/20 National
Gilead Boosts Cancer Drug Pipeline With $4.9B Deal for Forty Seven 03/02/20 San Francisco
ORIC Pharma Plans IPO to Test Therapies for Drug-Resistant Cancers 03/02/20 San Francisco
Xilio Unveils New Name, $100M to Bring Targeted Cancer Drugs to Clinic 03/02/20 Boston
Biogen, Sangamo Ink Neuro Deal for New “Gene Regulation” Therapies 02/28/20 National
Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More 02/28/20 National
Biohaven’s Migraine Pill Is the Latest CGRP Drug to Win the FDA’s OK 02/27/20 New York
Gilead, Moderna Candidates Ramp Up Coronavirus Drug, Vaccine Testing 02/27/20 National
With Foamix Merger Weeks Away, Menlo Itching Drug Fails a Phase 2 Test 02/26/20 San Francisco
NGM Bio’s NASH Drug Shows Promise, Shares Rise on Early Phase 2 Data 02/24/20 San Francisco
Lundbeck’s Alder Bio Bet Pays Off With FDA Approval of Migraine Drug 02/23/20 National
Bio Roundup: Agile Approval, Coronavirus Collabs, Spruce’s $88M & More 02/21/20 National
SeaGen Adds Five Prime Therapeutics Antibodies in Licensing Deal 02/20/20 Seattle
Spruce Bio Raises $88M for Clinical Tests of Rare Endocrine Disease Drug 02/20/20 San Francisco
Teva Drug Fails to Beat Placebo in Pediatric Tourette Patient Trials 02/19/20 National
Five Prime, Bristol Pancreatic Cancer Drug Combo Fails Phase 2 Test 02/18/20 San Francisco
Page 1 of 633 next page »